Retour

Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Stocks Earnings Releases and Operating Results

On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of 2024

GlobeNewswire Inc. • 07/05/2024 à 13:00:00
Neumora Therapeutics, Inc. Common Stock
Address: 490 ARSENAL WAY, SUITE 200
Postal Code: 02472
City: WATERTOWN
State: MA
Phone Number: (857) 760-0900
Website: https://www.neumoratx.com
Status: Active
Company Info

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

List Date2023-09-15
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001885522
Composite figiBBG012W9C4X1
Share Class figiBBG012W9C504
Market Cap1,542,597,051 USD
SIC Code2836
SIC DescriptionBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Total Employees120
Share Class Shares Outstanding159520000
Weighted Shares Outstanding159523997
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
9.675
9.635
9.67
9.575
8.955
Variance
0.44%
-0.36%
0.94%
6.9%
-2.05%
Open
9.633
9.67
9.58
8.957
9.142
Highest
9.686
10.034
9.727
9.618
9.433
Lowest
9.675
9.74
9.675
9.605
9.425
History
PeriodVarhighestlowest
1 week
5.83%
9.433
9.425
1 month
-10.54%
10.815
9.235
3 month
-49.99%
19.77
9.235
6 month
-19.58%
12.31
9.235
1 year
-41.36%
17.7394
9.235
3 year
-41.36%
17.7394
9.235
5 year
-41.36%
17.7394
9.235
10 year
-41.36%
17.7394
9.235
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2023-11-01 UNPUB
Assets UNPUB UNPUB 544,749,000 UNPUB
Current Assets UNPUB UNPUB 525,735,000 UNPUB
Current Liabilities UNPUB UNPUB 29,123,000 UNPUB
Equity UNPUB UNPUB 512,693,000 UNPUB
Equity Attributable To Noncontrolling Interest UNPUB UNPUB 0 UNPUB
Equity Attributable To Parent UNPUB UNPUB 512,693,000 UNPUB
Liabilities UNPUB UNPUB 32,056,000 UNPUB
Liabilities And Equity UNPUB UNPUB 544,749,000 UNPUB
Noncurrent Assets UNPUB UNPUB 19,014,000 UNPUB
Noncurrent Liabilities UNPUB UNPUB 2,933,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2023-11-01 UNPUB
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow UNPUB UNPUB UNPUB UNPUB
Net Cash Flow, Continuing UNPUB UNPUB UNPUB UNPUB
Net Cash Flow From Financing Activities UNPUB UNPUB UNPUB UNPUB
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB UNPUB UNPUB
Net Cash Flow From Investing Activities UNPUB UNPUB UNPUB UNPUB
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB UNPUB UNPUB
Net Cash Flow From Operating Activities UNPUB UNPUB UNPUB UNPUB
Net Cash Flow From Operating Activities, Continuing UNPUB UNPUB UNPUB UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2023-11-01 UNPUB
Comprehensive Income/Loss UNPUB UNPUB -52,890,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB 0 UNPUB
Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB -52,890,000 UNPUB
Other Comprehensive Income/Loss UNPUB UNPUB -52,890,000 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2023-11-01 UNPUB
Basic Earnings Per Share UNPUB UNPUB -1 UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB -1 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB UNPUB -53,027,000 UNPUB
Income/Loss From Continuing Operations Before Tax UNPUB UNPUB -53,027,000 UNPUB
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss UNPUB UNPUB -53,027,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB 0 UNPUB
Net Income/Loss Attributable To Parent UNPUB UNPUB -53,027,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic UNPUB UNPUB -53,027,000 UNPUB
Operating Expenses UNPUB UNPUB 56,864,000 UNPUB
Operating Income/Loss UNPUB UNPUB -56,864,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB UNPUB 0 UNPUB
Preferred Stock Dividends And Other Adjustments UNPUB UNPUB 0 UNPUB
Revenues UNPUB UNPUB 0 UNPUB
Calendar
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-17800.000
★
15:30
United States
-60000.000
★
15:30
United States
53700.000
★
15:30
United States
-135800.000
★★
15:30
United States
4400.000
★
15:30
United States
215400.000
★
15:30
United States
-31400.000
★
15:30
United States
62600.000
★
15:30
United States
1300.000
★
15:30
United States
-9700.000
★
15:30
United States
199600.000
★★
15:30
United States
★
15:30
United States
★
15:30
United States
★
15:30
United States
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:NMRA240517P00035000 OPASPS Put American 100 35 BATO 2024-05-17
O:NMRA240517P00030000 OPASPS Put American 100 30 BATO 2024-05-17
O:NMRA240517P00025000 OPASPS Put American 100 25 BATO 2024-05-17
O:NMRA240517P00022500 OPASPS Put American 100 22.5 BATO 2024-05-17
O:NMRA240517P00020000 OPASPS Put American 100 20 BATO 2024-05-17
O:NMRA240517P00017500 OPASPS Put American 100 17.5 BATO 2024-05-17
O:NMRA240517P00015000 OPASPS Put American 100 15 BATO 2024-05-17
O:NMRA240517P00012500 OPASPS Put American 100 12.5 BATO 2024-05-17
O:NMRA240517P00010000 OPASPS Put American 100 10 BATO 2024-05-17
O:NMRA240517P00007500 OPASPS Put American 100 7.5 BATO 2024-05-17
O:NMRA240517P00005000 OPASPS Put American 100 5 BATO 2024-05-17
O:NMRA240517P00002500 OPASPS Put American 100 2.5 BATO 2024-05-17
O:NMRA240517C00035000 OCASPS Call American 100 35 BATO 2024-05-17
O:NMRA240517C00030000 OCASPS Call American 100 30 BATO 2024-05-17
O:NMRA240517C00025000 OCASPS Call American 100 25 BATO 2024-05-17
O:NMRA240517C00022500 OCASPS Call American 100 22.5 BATO 2024-05-17
O:NMRA240517C00020000 OCASPS Call American 100 20 BATO 2024-05-17
O:NMRA240517C00017500 OCASPS Call American 100 17.5 BATO 2024-05-17
O:NMRA240517C00015000 OCASPS Call American 100 15 BATO 2024-05-17
O:NMRA240517C00012500 OCASPS Call American 100 12.5 BATO 2024-05-17
O:NMRA240517C00010000 OCASPS Call American 100 10 BATO 2024-05-17
O:NMRA240517C00007500 OCASPS Call American 100 7.5 BATO 2024-05-17
O:NMRA240517C00005000 OCASPS Call American 100 5 BATO 2024-05-17
O:NMRA240517C00002500 OCASPS Call American 100 2.5 BATO 2024-05-17
O:NMRA240419P00035000 OPASPS Put American 100 35 BATO 2024-04-19
O:NMRA240419P00030000 OPASPS Put American 100 30 BATO 2024-04-19
O:NMRA240419P00025000 OPASPS Put American 100 25 BATO 2024-04-19
O:NMRA240419P00022500 OPASPS Put American 100 22.5 BATO 2024-04-19
O:NMRA240419P00020000 OPASPS Put American 100 20 BATO 2024-04-19
O:NMRA240419P00017500 OPASPS Put American 100 17.5 BATO 2024-04-19
O:NMRA240419P00015000 OPASPS Put American 100 15 BATO 2024-04-19
O:NMRA240419P00012500 OPASPS Put American 100 12.5 BATO 2024-04-19
O:NMRA240419P00010000 OPASPS Put American 100 10 BATO 2024-04-19
O:NMRA240419P00007500 OPASPS Put American 100 7.5 BATO 2024-04-19
O:NMRA240419P00005000 OPASPS Put American 100 5 BATO 2024-04-19
O:NMRA240419C00035000 OCASPS Call American 100 35 BATO 2024-04-19
O:NMRA240419C00030000 OCASPS Call American 100 30 BATO 2024-04-19
O:NMRA240419C00025000 OCASPS Call American 100 25 BATO 2024-04-19
O:NMRA240419C00022500 OCASPS Call American 100 22.5 BATO 2024-04-19
O:NMRA240419C00020000 OCASPS Call American 100 20 BATO 2024-04-19
O:NMRA240419C00017500 OCASPS Call American 100 17.5 BATO 2024-04-19
O:NMRA240419C00015000 OCASPS Call American 100 15 BATO 2024-04-19
O:NMRA240419C00012500 OCASPS Call American 100 12.5 BATO 2024-04-19
O:NMRA240419C00010000 OCASPS Call American 100 10 BATO 2024-04-19
O:NMRA240419C00007500 OCASPS Call American 100 7.5 BATO 2024-04-19
O:NMRA240419C00005000 OCASPS Call American 100 5 BATO 2024-04-19
O:NMRA240419P00002500 OPASPS Put American 100 2.5 BATO 2024-04-19
O:NMRA240419C00002500 OCASPS Call American 100 2.5 BATO 2024-04-19
O:NMRA240315P00025000 OPASPS Put American 100 25 BATO 2024-03-15
O:NMRA240315P00022500 OPASPS Put American 100 22.5 BATO 2024-03-15
O:NMRA240315P00020000 OPASPS Put American 100 20 BATO 2024-03-15
O:NMRA240315P00017500 OPASPS Put American 100 17.5 BATO 2024-03-15
O:NMRA240315P00015000 OPASPS Put American 100 15 BATO 2024-03-15
O:NMRA240315P00012500 OPASPS Put American 100 12.5 BATO 2024-03-15
O:NMRA240315P00010000 OPASPS Put American 100 10 BATO 2024-03-15
O:NMRA240315P00007500 OPASPS Put American 100 7.5 BATO 2024-03-15
O:NMRA240315P00005000 OPASPS Put American 100 5 BATO 2024-03-15
O:NMRA240315P00002500 OPASPS Put American 100 2.5 BATO 2024-03-15
O:NMRA240315C00025000 OCASPS Call American 100 25 BATO 2024-03-15
O:NMRA240315C00022500 OCASPS Call American 100 22.5 BATO 2024-03-15
O:NMRA240315C00020000 OCASPS Call American 100 20 BATO 2024-03-15
O:NMRA240315C00017500 OCASPS Call American 100 17.5 BATO 2024-03-15
O:NMRA240315C00015000 OCASPS Call American 100 15 BATO 2024-03-15
O:NMRA240315C00012500 OCASPS Call American 100 12.5 BATO 2024-03-15
O:NMRA240315C00010000 OCASPS Call American 100 10 BATO 2024-03-15
O:NMRA240315C00007500 OCASPS Call American 100 7.5 BATO 2024-03-15
O:NMRA240315C00005000 OCASPS Call American 100 5 BATO 2024-03-15
O:NMRA240315C00002500 OCASPS Call American 100 2.5 BATO 2024-03-15
O:NMRA240216P00017500 OPASPS Put American 100 17.5 BATO 2024-02-16
O:NMRA240216P00015000 OPASPS Put American 100 15 BATO 2024-02-16
O:NMRA240216P00012500 OPASPS Put American 100 12.5 BATO 2024-02-16
O:NMRA240216P00010000 OPASPS Put American 100 10 BATO 2024-02-16
O:NMRA240216P00007500 OPASPS Put American 100 7.5 BATO 2024-02-16
O:NMRA240216C00017500 OCASPS Call American 100 17.5 BATO 2024-02-16
O:NMRA240216C00015000 OCASPS Call American 100 15 BATO 2024-02-16
O:NMRA240216C00012500 OCASPS Call American 100 12.5 BATO 2024-02-16
O:NMRA240216C00010000 OCASPS Call American 100 10 BATO 2024-02-16
O:NMRA240216C00007500 OCASPS Call American 100 7.5 BATO 2024-02-16
O:NMRA240216P00035000 OPASPS Put American 100 35 BATO 2024-02-16
O:NMRA240216P00030000 OPASPS Put American 100 30 BATO 2024-02-16
O:NMRA240216P00025000 OPASPS Put American 100 25 BATO 2024-02-16
O:NMRA240216P00022500 OPASPS Put American 100 22.5 BATO 2024-02-16
O:NMRA240216P00020000 OPASPS Put American 100 20 BATO 2024-02-16
O:NMRA240216P00005000 OPASPS Put American 100 5 BATO 2024-02-16
O:NMRA240216C00035000 OCASPS Call American 100 35 BATO 2024-02-16
O:NMRA240216C00030000 OCASPS Call American 100 30 BATO 2024-02-16
O:NMRA240216C00025000 OCASPS Call American 100 25 BATO 2024-02-16
O:NMRA240216C00022500 OCASPS Call American 100 22.5 BATO 2024-02-16
O:NMRA240216C00020000 OCASPS Call American 100 20 BATO 2024-02-16
O:NMRA240216C00005000 OCASPS Call American 100 5 BATO 2024-02-16
O:NMRA240119P00017500 OPASPS Put American 100 17.5 BATO 2024-01-19
O:NMRA240119P00015000 OPASPS Put American 100 15 BATO 2024-01-19
O:NMRA240119P00012500 OPASPS Put American 100 12.5 BATO 2024-01-19
O:NMRA240119P00010000 OPASPS Put American 100 10 BATO 2024-01-19
O:NMRA240119P00007500 OPASPS Put American 100 7.5 BATO 2024-01-19
O:NMRA240119C00017500 OCASPS Call American 100 17.5 BATO 2024-01-19
O:NMRA240119C00015000 OCASPS Call American 100 15 BATO 2024-01-19
O:NMRA240119C00012500 OCASPS Call American 100 12.5 BATO 2024-01-19
O:NMRA240119C00010000 OCASPS Call American 100 10 BATO 2024-01-19
O:NMRA240119C00007500 OCASPS Call American 100 7.5 BATO 2024-01-19
O:NMRA240119P00035000 OPASPS Put American 100 35 BATO 2024-01-19
O:NMRA240119P00030000 OPASPS Put American 100 30 BATO 2024-01-19
O:NMRA240119P00025000 OPASPS Put American 100 25 BATO 2024-01-19
O:NMRA240119P00022500 OPASPS Put American 100 22.5 BATO 2024-01-19
O:NMRA240119P00020000 OPASPS Put American 100 20 BATO 2024-01-19
O:NMRA240119P00005000 OPASPS Put American 100 5 BATO 2024-01-19
O:NMRA240119C00035000 OCASPS Call American 100 35 BATO 2024-01-19
O:NMRA240119C00030000 OCASPS Call American 100 30 BATO 2024-01-19
O:NMRA240119C00025000 OCASPS Call American 100 25 BATO 2024-01-19
O:NMRA240119C00022500 OCASPS Call American 100 22.5 BATO 2024-01-19
O:NMRA240119C00020000 OCASPS Call American 100 20 BATO 2024-01-19
O:NMRA240119C00005000 OCASPS Call American 100 5 BATO 2024-01-19
O:NMRA231117P00017500 OPASPS Put American 100 17.5 BATO 2023-11-17
O:NMRA231117P00015000 OPASPS Put American 100 15 BATO 2023-11-17
O:NMRA231117P00012500 OPASPS Put American 100 12.5 BATO 2023-11-17
O:NMRA231117P00010000 OPASPS Put American 100 10 BATO 2023-11-17
O:NMRA231117P00007500 OPASPS Put American 100 7.5 BATO 2023-11-17
O:NMRA231117C00017500 OCASPS Call American 100 17.5 BATO 2023-11-17
O:NMRA231117C00015000 OCASPS Call American 100 15 BATO 2023-11-17
O:NMRA231117C00012500 OCASPS Call American 100 12.5 BATO 2023-11-17
O:NMRA231117C00010000 OCASPS Call American 100 10 BATO 2023-11-17
O:NMRA231117C00007500 OCASPS Call American 100 7.5 BATO 2023-11-17
News Stream
News Clinical Study
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to improve these symptoms in MDD in a Phase 2 study
GlobeNewswire Inc. • 5d ago
Stocks Earnings Releases and Operating Results
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of 2024
GlobeNewswire Inc. • 1w ago
Calendar Calendar of Events
Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will participate in a fireside chat at the Stifel 2024 Virtual CNS Days on Wednesday, March 20, 2024 at 11:00 a.m. ET.
GlobeNewswire Inc. • 2mo ago
Management Directors and Officers
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer
WATERTOWN, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Kaya Pai Panandiker as chief commercial officer and a member of Neumora’s executive team, reporting to Henry Gosebruch, president and chief executive officer. Ms. Pai Panandiker has more than 20 years of experience commercializing medicines in areas of significant unmet need, including the commercial launches of TRINTELLIX® (vortioxetine) and REXULTI® (brexpiprazole) for major depressive disorder (MDD) and schizophrenia.
GlobeNewswire Inc. • 3mo ago
News News
Why Neumora Therapeutics (NMRA) Stock Might be a Great Pick
Neumora Therapeutics (NMRA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Zacks Investment Research • 4mo ago
Calendar Calendar of Events
Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
WATERTOWN, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Monday, January 8, 2024 at 11:15 a.m. PT (2:15 p.m. ET).
GlobeNewswire Inc. • 4mo ago
News Clinical Study
Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study
NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment of schizophrenia NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment of schizophrenia
GlobeNewswire Inc. • 5mo ago
Analyst Analyst Ratings
Analyst Expectations for Neumora Therapeutics's Future
Within the last quarter, Neumora Therapeutics (NASDAQ:NMRA) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 3 0 0 0 Last 30D 0 1 0 0 0 1M Ago 3 2 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 According to 6 analyst offering 12-month price targets in the last 3 months, Neumora Therapeutics has an ...Full story available on Benzinga.com
Benzinga • 6mo ago
Calendar Calendar of Events
Neumora Therapeutics to Participate in Upcoming Conferences in November
WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will participate in two investor conferences in November:
GlobeNewswire Inc. • 6mo ago
Analyst Analyst Color
Why Neumora Therapeutics Analysts Are Bullish About Major Depressive Disorder Drug
Shares of Neumora Therapeutics Inc (NASDAQ: NMRA) were trading lower on Tuesday, a month after the company announced its IPO on the NASDAQ exchange. RBC Capital Markets On Neumora Therapeutics Analyst Brian Abrahams initiated coverage with an Outperform rating and price target of $24. Neumora Therapeutics’ lead drug navacaprant showed statistically significant results in the Hamilton Rating Scale for Depression (HAM-D) in major depressive disorder (MDD), “in our view clinically meaningful in the context of existing SoC,” Abrahams said in the initiation note. “Despite historical MDD indication challenges, ...Full story available on Benzinga.com
Benzinga • 7mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT